|
1
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Song Z, Yu X and Zhang Y: Mutation and
prognostic analyses of PIK3CA in patients with completely
resected lung adenocarcinoma. Cancer Med. 5:2694–2700.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mattiuzzi C, Sanchis-Gomar F and Lippi G:
Concise update on colorectal cancer epidemiology. Ann Transl Med.
7(609)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dafni U, Tsourti Z and Alatsathianos I:
Breast cancer statistics in the european union: Incidence and
survival across european countries. Breast Care. 14:344–353.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Franczak C, Filhine-Tressarieu P, Broséus
J, Gilson P, Merlin JL and Harlé A: Clinical interest of
circulating tumor DNA in oncology. Arch Med Res. 49:297–305.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Arneth B: Update on the types and usage of
liquid biopsies in the clinical setting: A systematic review. BMC
Cancer. 18(527)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lindeman NI, Cagle PT, Aisner DL, Arcila
ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr
K, et al: Updated molecular testing guideline for the selection of
lung cancer patients for treatment with targeted tyrosine kinase
inhibitors: Guideline from the college of American pathologists,
the international association for the study of lung cancer, and the
association for molecular pathology. Arch Pathol Lab Med.
142:321–346. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Von Bubnoff N: Liquid biopsy: Approaches
to dynamic genotyping in cancer. Oncol Res Treat. 40:409–416.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bronte G, Ulivi P, Verlicchi A, Cravero P,
Delmonte A and Crinò L: Targeting RET-rearranged non-small-cell
lung cancer: Future prospects. Lung Cancer (Auckl). 10:27–36.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Oxnard GR, Thress KS, Alden RS, Lawrance
R, Paweletz CP, Cantarini M, Yang JC, Barrett JC and Jänne PA:
Association between plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
J Clin Oncol. 34:3375–3382. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu S, Li S, Wang B, Liu W, Gagea M, Chen
H, Sohn J, Parinyanitikul N, Primeau T, Do KA, et al: Cooperative
effect of oncogenic MET and PIK3CA in an HGF-dominant
environment in breast cancer. Mol Cancer Ther. 18:399–412.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tan AC: Targeting the PI3K/Akt/mTOR
pathway in non-small cell lung cancer (NSCLC). Thorac Cancer.
11:511–518. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gkountakos A, Sartori G, Falcone I, Piro
G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M,
et al: PTEN in lung cancer: Dealing with the problem,
building on new knowledge and turning the game around. Cancers
(Basel). 11(1141)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jaiswal S, Fontanillas P, Flannick J,
Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N,
Chavez A, et al: Age-related clonal hematopoiesis associated with
adverse outcomes. N Engl J Med. 371:2488–2498. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Snyder MW, Kircher M, Hill AJ, Daza RM and
Shendure J: Cell-free DNA comprises an in vivo nucleosome footprint
that informs its tissues-of-origin. Cell. 164:57–68.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gupta S, Provenzale D, Llor X, Halverson
AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP Jr,
Hampel H, et al: NCCN guidelines insights: Genetic/familial
high-risk assessment: Colorectal, version 2.2019. J Natl Compr
Cancer Netw. 17:1032–1041. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Daly MB, Pilarski R, Yurgelun MB, Berry
MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber
JE, et al: NCCN guidelines insights: Genetic/familial high-risk
assessment: Breast, ovarian, and pancreatic, version 1.2020. J Natl
Compr Cancer Netw. 18:380–391. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li MM, Datto M, Duncavage EJ, Kulkarni S,
Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ,
Younes A and Nikiforova MN: Standards and guidelines for the
interpretation and reporting of sequence variants in cancer: A
joint consensus recommendation of the association for molecular
pathology, american society of clinical oncology, and college of
american pathologists. J Mol Diagnostics. 19:4–23. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jay JJ and Brouwer C: Lollipops in the
clinic: Information dense mutation plots for precision medicine.
PLoS One. 11(e0160519)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Guo Y, Song J, Wang Y, Huang L, Sun L,
Zhao J, Zhang S, Jing W, Ma J and Han C: Concurrent genetic
alterations and other biomarkers predict treatment efficacy of
egfr-tkis in EGFR-mutant non-small cell lung cancer: A Review.
Front Oncol. 10(610923)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chang WJ, Sung JS, Lee SY, Kang EJ, Kwon
NJ, Kim HM, Shin SW, Choi JY, Choi YJ, Kim JW, et al: The clinical
significance of RAS, PIK3CA, and PTEN mutations in
non-small cell lung cancer using cell-free DNA. J Clin Med.
14(2642)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Matsuo N, Azuma K, Sakai K, Hattori S,
Kawahara A, Ishii H, Tokito T, Kinoshita T, Yamada K, Nishio K and
Hoshino T: Association of EGFR Exon 19 deletion and EGFR-TKI
treatment duration with frequency of T790M mutation in EGFR-mutant
lung cancer patients. Sci Rep. 6(36458)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shaw AT, Friboulet L, Leshchiner I, Gainor
JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, et
al: Resensitization to crizotinib by the lorlatinib ALK resistance
mutation L1198F . N Engl J Med. 374:54–61. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Thierry AR, El Messaoudi S, Mollevi C,
Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C,
Mathonnet M, et al: Clinical utility of circulating DNA analysis
for rapid detection of actionable mutations to select metastatic
colorectal patients for anti-EGFR treatment. Ann Oncol.
28:2149–2159. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Formica V, Lucchetti J, Doldo E, Riondino
S, Morelli C, Argirò R, Renzi N, Nitti D, Nardecchia A, Dell'Aquila
E, et al: Clinical utility of plasma KRAS, NRAS and
BRAF mutational analysis with real time PCR in metastatic
colorectal cancer patients-the importance of tissue/plasma
discordant cases. J Clin Med. 10(87)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA (eds): SEER
Cancer Statistics Review, 1975-2012, National Cancer Institute.
Bethesda, MD, based on November 2014 SEER data submission, posted
to the SEER web site, 2015. https://seer.cancer.gov/archive/csr/1975_2012.
Accessed November 18, 2015.
|
